Table 1.
Comparisons of patient characteristics between treatment groups
| Group I (n = 14) | Group II (n = 14) | Total (n = 28) | p | |
|---|---|---|---|---|
| Age (years) | 54.9 ± 13.2 | 59.0 ± 10.4 | 56.9 ± 11.9 | 0.511 |
| Sex | 1.000 | |||
| Male | 5 (35.7) | 5 (35.7) | 10 (35.7) | |
| Female | 9 (64.3) | 9 (64.3) | 18 (34.3) | |
| Smokers | 1 (7.1) | 2 (14.3) | 3 (10.7) | 0.769 |
| Hypertension | 6 (42.9) | 4 (28.6) | 10 (35.7) | 0.449 |
| Diabetic mellitus | 1 (7.1) | 3 (21.4) | 4 (24.3) | 0.297 |
| Axial length (mm) | 23.79 ± 1.02 | 23.80 ± 1.20 | 23.79 ± 1.10 | 0.964 |
| Intraocular pressure (mmHg) | 17.0 ± 5.4 | 17.7 ± 3.6 | 17.4 ± 4.6 | 0.582 |
| Duration of hyperthyroidism (years) | 1.1 ± 1.4 | 2.3 ± 3.5 | 1.7 ± 2.7 | 0.635 |
| Duration of TAO (months) | 1.9 ± 3.0 | 2.5 ± 3.1 | 2.2 ± 3.0 | 0.642 |
| Thyroid hormone | ||||
| T3 | 4 (28.6) | 3 (21.4) | 7 (25.0) | 0.769 |
| Free T4 | 3 (21.4) | 3 (21.4) | 6 (21.4) | 1.000 |
| Thyroid antibody | ||||
| Thyroid stimulating antibody | 13 (92.9) | 13 (92.9) | 26 (92.9) | 1.000 |
| TSH receptor antibody | 9 (64.3) | 8 (57.1) | 17 (60.7) | 0.769 |
| Anti thyroid peroxidase antibody | 3 (21.4) | 7 (50.0) | 10 (35.7) | 0.21 |
| Thyroglobulin antibody | 0 (0.0) | 2 (14.3) | 2 (7.1) | 0.541 |
TAO, thyroid-associated ophthalmopathy; TSH, thyroid stimulating hormone
a
Data are presented as the means ± standard deviation or numbers with percentages in parentheses.